{"organizations": [], "uuid": "45606b67bd73dddaf7af48009eb4195bb6d9a4e6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-intercept-announces-updated-us-pre/brief-intercept-announces-updated-u-s-prescribing-information-for-ocaliva-idUSFWN1PR0X0", "country": "US", "domain_rank": 408, "title": "BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T17:09:00.000+02:00", "replies_count": 0, "uuid": "45606b67bd73dddaf7af48009eb4195bb6d9a4e6"}, "author": "", "url": "https://www.reuters.com/article/brief-intercept-announces-updated-us-pre/brief-intercept-announces-updated-u-s-prescribing-information-for-ocaliva-idUSFWN1PR0X0", "ord_in_thread": 0, "title": "BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ocaliva reuters staff", "sentiment": "none"}, {"name": "reuters) - intercept pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 1, 2018 / 3:10 PM / in 11 minutes BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva Reuters Staff 2 Min Read \nFeb 1 (Reuters) - Intercept Pharmaceuticals Inc: \n* INTERCEPT ANNOUNCES UPDATED U.S. PRESCRIBING INFORMATION FOR OCALIVA® (OBETICHOLIC ACID) TO REINFORCE APPROPRIATE DOSING IN PBC PATIENTS WITH ADVANCED CIRRHOSIS \n* INTERCEPT PHARMACEUTICALS INC - OCALIVA LABEL HAS BEEN REVISED TO INCLUDE A BOXED WARNING \n* INTERCEPT PHARMACEUTICALS INC - INTERCEPT WILL BE DISSEMINATING UPDATED PRESCRIBING INFORMATION AND A MEDICATION GUIDE FOR PATIENTS \n* INTERCEPT PHARMACEUTICALS INC - OCALIVA LABEL HAS BEEN REVISED TO INCLUDE A DOSING TABLE THAT REINFORCE EXISTING DOSING SCHEDULE FOR CERTAIN PATIENTS \n* INTERCEPT PHARMACEUTICALS INC - U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED AN UPDATED DRUG SAFETY COMMUNICATION TO ACCOMPANY LABEL \n* INTERCEPT PHARMACEUTICALS INC - UPDATED LABEL REINFORCES POSITIVE BENEFIT-RISK PROFILE OF OCALIVA WHEN USED AS DIRECTED \n* INTERCEPT PHARMACEUTICALS - TABLE IS INCLUDED IN UPDATED PRESCRIBING INFORMATION TO INCREASE PROMINENCE OF RECOMMENDED OCALIVA DOSAGE BY DISEASE STAGE \n* INTERCEPT PHARMA - TABLE INCLUDED UPDATED PRESCRIBING INFORMATION TO INCREASE PROMINENCE OF RECOMMENDED OCALIVA DOSAGE BY CHILD-PUGH CLASSIFICATION \n* INTERCEPT PHARMACEUTICALS - ALSO WORKING WITH EMA TO UPDATE OCALIVA EUROPEAN SMPC TO REINFORCE APPROPRIATE DOSING IN PATIENTS WITH ADVANCED CIRRHOSIS \n* INTERCEPT - CO‘S RECENT ASSESSMENT OF POSTMARKETING DATA DID NOT ESTABLISH CAUSAL RELATIONSHIP BETWEEN OCALIVA&LIVER DECOMPENSATION &/LIVER FAILURE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-01T17:09:00.000+02:00", "crawled": "2018-02-01T17:33:59.017+02:00", "highlightTitle": ""}